By comparing heterozygous TP53 mutated cells from patients in MPN-CP before leukemic transformation with the same cells from patients who did not evolve to sAML, the central role of inflammation in leukemic evolution was highlighted. The gene discussed is TP53; the disease is myeloproliferative disorder.